Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 36Thoracic 7Genitourinary 6Gynecologic 5Dermatologic 5Breast 5Sarcoma 4Head & Neck 4CNS 4Other hematologic neoplasm 2NET 2Lymphoid 2Endocrine 2Plasma cell 1

Conditions

Lymphoma, Large B-Cell, Diffuse 39Lymphoma 34Lymphoma, Follicular 24Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 19Lymphoma, B-Cell 16Leukemia, Lymphocytic, Chronic, B-Cell 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Burkitt Lymphoma 14Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Large-Cell, Anaplastic 8Glioma 8Neuroectodermal Tumors, Primitive, Peripheral 7Neuroblastoma 7Mycosis Fungoides 7Lymphoma, T-Cell 7Histiocytosis, Langerhans-Cell 7Wilms Tumor 6Waldenstrom Macroglobulinemia 6Sarcoma 6Rhabdoid Tumor 6Medulloblastoma 6Lymphoma, T-Cell, Cutaneous 6Hepatoblastoma 6Ependymoma 6Rhabdomyosarcoma 5Osteosarcoma 5

Interventions

fludarabine 4Cyclophosphamide 4pembrolizumab 3Specimen Handling 3aflibercept 2X-Rays 2Nivolumab 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Dasatinib 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1epacadostat 1entinostat 1dostarlimab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Magnetic Resonance Spectroscopy × Lymphoid × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡